140462-76-6 | Olopatadine HCl

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$7.00	$5.00
50mg	98%	in stock	$10.00	$7.00
250mg	98%	in stock	$16.00	$11.00
1g	98%	in stock	$36.00	$25.00
25g	98%	in stock	$491.00	$344.00

Description

• Catalog Number: AA62640
• Chemical Name: Olopatadine HCl
• CAS Number: 140462-76-6
• Molecular Formula: C21H24ClNO3
• Molecular Weight: 373.8732
• MDL Number: MFCD00875716
• SMILES: CN(CC/C=C/1\c2cc(ccc2OCc2c1cccc2)CC(=O)O)C.Cl

Computed Properties

• Complexity: 488
• Covalently-Bonded Unit Count: 2
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5

Literature

• Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis.

  Experimental dermatology 20120901

• [A 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in Japan].

  Nippon Ganka Gakkai zasshi 20120901

• The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice.

  Allergy 20120801

• Stereoselective syntheses of the antihistaminic drug olopatadine and its E-isomer.

  The Journal of organic chemistry 20120720

• Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

  Clinical therapeutics 20120601

• Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.

  Archives of dermatological research 20120501

• The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats.

  Biological & pharmaceutical bulletin 20120101

• Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis.

  Expert opinion on drug metabolism & toxicology 20111201

• Thermal angiooedema induced by hot water.

  Acta dermato-venereologica 20110501

• Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.

  American journal of ophthalmology 20110401

• A rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of olopatadine concentration in human plasma.

  Journal of analytical toxicology 20110301

• Intrastromal corneal ring segments for bilateral keratoconus in an 11-year-old boy.

  Journal of cataract and refractive surgery 20110101

• Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.

  Drug design, development and therapy 20110101

• Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans.

  Pharmacology 20110101

• Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.

  Allergy and asthma proceedings 20110101

• Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis.

  Allergy and asthma proceedings 20110101

• Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.

  American journal of rhinology & allergy 20110101

• Olopatadine suppresses the late phase reaction in parthenium dermatitis.

  Indian journal of dermatology, venereology and leprology 20110101

• Stability-indicating high-performance column liquid chromatography and high-performance thin-layer chromatography methods for the determination of olopatadine hydrochloride in tablet dosage form.

  Journal of AOAC International 20110101

• Dermatitis induced by estrogen and progesterone: dual positive results on the intradermal skin test.

  Dermatitis : contact, atopic, occupational, drug 20110101

• Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis.

  Current medical research and opinion 20100701

• Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.

  Eye & contact lens 20100701

• Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older.

  Expert opinion on pharmacotherapy 20100601

• Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.

  Expert opinion on pharmacotherapy 20100401

• Olopatadine nasal spray for the treatment of allergic rhinitis.

  Expert review of clinical immunology 20100301

• Histamine stimulates interleukin-6 production through histamine H1 receptors in human amnion cells.

  Gynecologic and obstetric investigation 20100101

• Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis.

  Allergy and asthma proceedings 20100101

• Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.

  European journal of ophthalmology 20100101

• [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].

  [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101

• Comprehensive review of olopatadine: the molecule and its clinical entities.

  Allergy and asthma proceedings 20100101

• Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice.

  International archives of allergy and immunology 20100101

• Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice.

  Pharmacology 20100101

• Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study.

  Allergy and asthma proceedings 20100101

• Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.

  The Journal of dermatology 20091201

• Olopatadine hydrochloride inhibits scratching behavior induced by a proteinase-activated receptor 2 agonist in mice.

  Journal of dermatological science 20091101

• Azelastine and olopatadine in the treatment of allergic rhinitis.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20091101

• Multiple action agents and the eye: do they really stabilize mast cells?

  Current opinion in allergy and clinical immunology 20091001

• Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.

  Acta ophthalmologica 20090801

• Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090601

• Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride.

  The Journal of dermatology 20090401

• Drug approvals: '08 in review. Olopatadine hydrochloride (Patanase) nasal spray.

  The Nurse practitioner 20090201

• Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis.

  Journal of dermatological science 20090101

• Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.

  Clinical therapeutics 20090101

• Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis?

  Allergy and asthma proceedings 20090101

• Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study.

  Clinical drug investigation 20090101

• Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis.

  Allergy and asthma proceedings 20090101

• Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

  BMC ophthalmology 20090101

• Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit.

  Journal of investigational allergology & clinical immunology 20090101

• Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.

  Pharmacology 20090101

• Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis.

  Allergy and asthma proceedings 20090101

• [Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis].

  Oftalmologia (Bucharest, Romania : 1990) 20090101

• [Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis].

  Revista medica del Instituto Mexicano del Seguro Social 20090101

• Comparison of the conjunctival toxicity of topical ocular antiallergic agents.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081201

• Repeated pre-treatment with antihistamines suppresses [corrected] transcriptional up-regulations of histamine H(1) receptor and interleukin-4 genes in toluene-2,4-diisocyanate-sensitized rats.

  Journal of pharmacological sciences 20081201

• Effects of olopatadine in limited scleroderma with peripheral eosinophils.

  Geriatrics & gerontology international 20080901

• Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis.

  Archives of dermatological research 20080701

• The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20080701

• Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.

  International immunopharmacology 20080601

• Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.

  Experimental eye research 20080501

• Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.

  Expert opinion on drug metabolism & toxicology 20080401

• Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.

  Methods and findings in experimental and clinical pharmacology 20080401

• Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.

  Current medical research and opinion 20080201

• Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function.

  Pharmacology 20080101

• The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism.

  Pharmacology 20080101

• P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist.

  Drug metabolism and pharmacokinetics 20080101

• Enhancement of basophil apoptosis by olopatadine and theophylline.

  Allergy and asthma proceedings 20080101

• A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.

  Allergy and asthma proceedings 20080101

• Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%.

  Allergy and asthma proceedings 20080101

• Use of olopatadine ophthalmic solution and reactivity of histamine skin testing.

  Allergy and asthma proceedings 20080101

• An assessment of the onset and duration of action of olopatadine nasal spray.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20071201

• Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.

  Current eye research 20071201

• Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20071101

• [Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070901

• Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801

• Safety and tolerability of olopatadine 0.2% in children and adolescents.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801

• The effect of H1 antagonists carebastine and olopatadine on histamine induced expression of CC chemokines in cultured human nasal epithelial cells.

  Allergology international : official journal of the Japanese Society of Allergology 20070601

• Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.

  Current medical research and opinion 20070601

• Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice.

  The British journal of dermatology 20070501

• Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070201

• Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines.

  Journal of investigational allergology & clinical immunology 20070101

• Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.

  Allergy and asthma proceedings 20070101

• Chronic red eyes. Diagnosis: allergic conjunctivitis due to airborne allergen.

  Comprehensive ophthalmology update 20070101

• Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate.

  Allergy and asthma proceedings 20070101

• Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.

  Advances in therapy 20070101

• Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis.

  Allergy and asthma proceedings 20070101

• Olopatadine attenuates the enhancement of capsaicin-evoked substance P release by bradykinin from cultured dorsal root ganglion neurons.

  European journal of pharmacology 20061215

• Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.

  Eye & contact lens 20061201

• Neuronal conditions of spinal cord in dermatitis are improved by olopatadine.

  European journal of pharmacology 20061010

• [Clinical effects of olopatadine hydrochloride on pruritus in skin diseases].

  Arerugi = [Allergy] 20061001

• Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.

  Clinical therapeutics 20061001

• [The use of 'Antigrippin-maximum' in the complex therapy of patients with acute respiratory diseases].

  Voenno-meditsinskii zhurnal 20061001

• [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].

  Orvosi hetilap 20060910

• Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK.

  Current medical research and opinion 20060901

• Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment.

  Investigative ophthalmology & visual science 20060801

• [Misleading advertisement on Opatanol].

  Nederlands tijdschrift voor geneeskunde 20060701

• Pharmacotherapy of allergic eye disease.

  Expert opinion on pharmacotherapy 20060601

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Red, itchy eyes, giant papillae.

  Advance for nurse practitioners 20060301

• Role of substance P in allergic nasal symptoms in rats.

  European journal of pharmacology 20060217

• Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.

  Acta ophthalmologica Scandinavica 20060201

• Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.

  British journal of clinical pharmacology 20060101

• Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.

  Mediators of inflammation 20060101

• Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo.

  Allergy and asthma proceedings 20060101

• [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].

  Arquivos brasileiros de oftalmologia 20060101

• Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice.

  Pharmacology 20051201

• Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051201

• The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice.

  European journal of pharmacology 20051107

• Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051101

• Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20051001

• Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051001

• The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis.

  The Journal of dermatology 20051001

• Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.

  Current medical research and opinion 20050901

• Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.

  Clinical therapeutics 20050901

• Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.

  Current medical research and opinion 20050501

• A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.

  Clinical therapeutics 20050501

• Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.

  Ocular immunology and inflammation 20050201

• [Examination of effectiveness of olopatadine hydrochloride in atopic dermatitis].

  Arerugi = [Allergy] 20050201

• Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20050101

• Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis.

  The Journal of dermatology 20050101

• Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis.

  Journal of dermatological science 20041201

• Effects of olopatadine hydrochloride, an antihistamine drug, on skin inflammation induced by repeated topical application of oxazolone in mice.

  The British journal of dermatology 20041201

• Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.

  Current medical research and opinion 20041201

• A review of olopatadine for the treatment of ocular allergy.

  Expert opinion on pharmacotherapy 20040901

• Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance.

  Clinical and experimental dermatology 20040901

• Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.

  Current medical research and opinion 20040801

• Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.

  Current medical research and opinion 20040801

• Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.

  Clinical therapeutics 20040801

• Ocular allergy treatment comparisons: azelastine and olopatadine.

  Current allergy and asthma reports 20040701

• A review of the use of olopatadine in allergic conjunctivitis.

  International ophthalmology 20040501

• Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells.

  Biochemical pharmacology 20040401

• [Olopatadine].

  Revue de l'infirmiere 20040401

• The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20040101

• Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.

  Allergy and asthma proceedings 20040101

• Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.

  Arzneimittel-Forschung 20040101

• Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers.

  Human psychopharmacology 20031201

• Interactions of olopatadine and selected antihistamines with model and natural membranes.

  Ocular immunology and inflammation 20031201

• Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.

  Clinical therapeutics 20031001

• Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.

  Acta ophthalmologica Scandinavica 20030801

• Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.

  Clinical therapeutics 20030801

• [Opatanol].

  Ugeskrift for laeger 20030721

• One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.

  Clinical therapeutics 20030701

• Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells.

  Cellular immunology 20030701

• Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.

  Eye & contact lens 20030401

• [In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].

  Journal francais d'ophtalmologie 20030401

• Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.

  International archives of allergy and immunology 20030301

• A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.

  Clinical therapeutics 20030301

• Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.

  Advances in therapy 20030101

• Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.

  Clinical therapeutics 20021001

• Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.

  Clinical therapeutics 20020901

• Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study.

  Clinical therapeutics 20020801

• Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.

  Clinical therapeutics 20020701

• Occupational allergy caused by Peruvian lily (Alstroemeria).

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020601

• Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.

  Clinical therapeutics 20020601

• Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020501

• Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.

  Biochemical and biophysical research communications 20020412

• Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.

  Japanese journal of pharmacology 20020401

• Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils.

  Japanese journal of pharmacology 20020401

• Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.

  Allergy and asthma proceedings 20020101

• Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20011101

• Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats.

  Japanese journal of pharmacology 20011001

• Mucus fishing syndrome: case report and new treatment option.

  Optometry (St. Louis, Mo.) 20011001

• Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.

  Clinical therapeutics 20010801

• [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010701

• Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010601

• [Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval in dogs].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010601

• Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs.

  Japanese journal of pharmacology 20010601

• Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs.

  Japanese journal of pharmacology 20010401

• Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201

• The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 19960101